Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

505
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
505
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

59
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
59
Multicompartment Models: Overview01:14

Multicompartment Models: Overview

65
Multicompartment models are mathematical constructs that depict how drugs are distributed and eliminated within the body. They segment the body into several compartments, symbolizing various physiological or anatomical areas connected through drug transfer processes such as absorption, metabolism, distribution, and elimination.
These models offer a more comprehensive representation of drug behavior in the body than one-compartment models. They accommodate the complexity of drug distribution,...
65
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

24
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
24
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

47
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
47
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

22
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
22

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacogenomics and chronotherapy of drug-induced cardioprotection in acute myocardial infarction.

Nature communications·2025
Same author

Protein-Protein Binding Kinetics by Biolayer Interferometry.

Advances in experimental medicine and biology·2024
Same author

X-Ray Crystallography for Macromolecular Complexes.

Advances in experimental medicine and biology·2024
Same author

The crystal structure of iC3b-CR3 αI reveals a modular recognition of the main opsonin iC3b by the CR3 integrin receptor.

Nature communications·2022
Same author

Structures of T7 bacteriophage portal and tail suggest a viral DNA retention and ejection mechanism.

Nature communications·2019
Same author

Insights into the inhibited form of the redox-sensitive SufE-like sulfur acceptor CsdE.

PloS one·2017

Related Experiment Video

Updated: Jun 23, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

C-model: A comprehensive enhanced pharmacokinetic/pharmacodynamic simulation environment targeting the complement

Lucía Alfonso-González1,2, M Cristina Vega2, Francisco J Fernández1

  • 1Abvance Biotech SL, Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM), Madrid, Spain.

British Journal of Pharmacology
|May 12, 2025
PubMed
Summary
This summary is machine-generated.

A new computational model, C-model, effectively predicts complement biomarkers and treatment responses in various diseases. This tool aids in developing new therapies and personalizing patient care for complement-related conditions.

Keywords:
C3 glomerulopathyC‐modelatypical haemolytic uraemic syndromecomplement systemdense deposit diseaseenhanced PK/PD

More Related Videos

A Modeling and Simulation Method for Preliminary Design of an Electro-Variable Displacement Pump
09:04

A Modeling and Simulation Method for Preliminary Design of an Electro-Variable Displacement Pump

Published on: June 1, 2022

Realistic Membrane Modeling Using Complex Lipid Mixtures in Simulation Studies
07:31

Realistic Membrane Modeling Using Complex Lipid Mixtures in Simulation Studies

Published on: September 1, 2023

Related Experiment Videos

Last Updated: Jun 23, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

A Modeling and Simulation Method for Preliminary Design of an Electro-Variable Displacement Pump
09:04

A Modeling and Simulation Method for Preliminary Design of an Electro-Variable Displacement Pump

Published on: June 1, 2022

Realistic Membrane Modeling Using Complex Lipid Mixtures in Simulation Studies
07:31

Realistic Membrane Modeling Using Complex Lipid Mixtures in Simulation Studies

Published on: September 1, 2023

Area of Science:

  • Immunology
  • Computational Biology
  • Pharmacodynamics

Background:

  • The complement system is crucial in numerous diseases, but treatment is challenging due to disease heterogeneity and varied responses.
  • Understanding complement activation pathways and regulation is vital for effective disease management.

Purpose of the Study:

  • To introduce C-model, a comprehensive computational environment for simulating the complement system.
  • To address challenges in managing complement-related diseases through advanced modeling.

Main Methods:

  • C-model simulates alternative, classical, and lectin complement activation pathways, plus the terminal/lytic pathway.
  • The model incorporates fluid phase and cell-associated regulation (erythrocytes, endothelial cells).
  • It integrates experimental patient data and simulated drug effects.

Main Results:

  • C-model accurately forecasts complement biomarkers in healthy and diseased states.
  • The model predicts patient responses to various therapeutic interventions.
  • Simulation data is publicly available for academic research.

Conclusions:

  • C-model is an advanced pharmacokinetic/pharmacodynamic tool supporting novel therapy development.
  • It facilitates personalized patient management by enabling scenario simulations.
  • The model enhances understanding of the complement system's role in disease.